These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 31745860)

  • 1. Serum beta-secretase 1 (BACE1) activity as candidate biomarker for late-onset Alzheimer's disease.
    Cervellati C; Trentini A; Rosta V; Passaro A; Bosi C; Sanz JM; Bonazzi S; Pacifico S; Seripa D; Valacchi G; Guerini R; Zuliani G
    Geroscience; 2020 Feb; 42(1):159-167. PubMed ID: 31745860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum beta-secretase 1 (BACE1) activity increases in patients with mild cognitive impairment.
    Zuliani G; Trentini A; Brombo G; Rosta V; Guasti P; Romagnoli T; Polastri M; Marabini L; Pedrini D; Pistolesi C; Pacifico S; Guerrini R; Seripa D; Cervellati C
    J Neurochem; 2021 Nov; 159(3):629-637. PubMed ID: 34534363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment.
    Shen Y; Wang H; Sun Q; Yao H; Keegan AP; Mullan M; Wilson J; Lista S; Leyhe T; Laske C; Rujescu D; Levey A; Wallin A; Blennow K; Li R; Hampel H
    Biol Psychiatry; 2018 Mar; 83(5):447-455. PubMed ID: 28359566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased Serum Beta-Secretase 1 Activity is an Early Marker of Alzheimer's Disease.
    Nicsanu R; Cervellati C; Benussi L; Squitti R; Zanardini R; Rosta V; Trentini A; Ferrari C; Saraceno C; Longobardi A; Bellini S; Binetti G; Zanetti O; Zuliani G; Ghidoni R
    J Alzheimers Dis; 2022; 87(1):433-441. PubMed ID: 35275540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased blood BACE1 activity as a potential common pathogenic factor of vascular dementia and late onset Alzheimer's disease.
    Zuliani G; Trentini A; Rosta V; Guerrini R; Pacifico S; Bonazzi S; Guiotto A; Passaro A; Seripa D; Valacchi G; Cervellati C
    Sci Rep; 2020 Sep; 10(1):14980. PubMed ID: 32917964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum Beta-Secretase 1 Activity Is a Potential Marker for the Differential Diagnosis between Alzheimer's Disease and Frontotemporal Dementia: A Pilot Study.
    Saraceno C; Cervellati C; Trentini A; Crescenti D; Longobardi A; Geviti A; Bonfiglio NS; Bellini S; Nicsanu R; Fostinelli S; Mola G; Riccetti R; Moretti DV; Zanetti O; Binetti G; Zuliani G; Ghidoni R
    Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal Fluid BACE1 Activity and sAβPPβ as Biomarker Candidates of Alzheimer's Disease.
    Alexopoulos P; Thierjung N; Grimmer T; Ortner M; Economou P; Assimakopoulos K; Gourzis P; Politis A; Perneczky R;
    Dement Geriatr Cogn Disord; 2018; 45(3-4):152-161. PubMed ID: 29788013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of plasma β-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's disease.
    Wu G; Sankaranarayanan S; Wong J; Tugusheva K; Michener MS; Shi X; Cook JJ; Simon AJ; Savage MJ
    J Neurosci Res; 2012 Dec; 90(12):2247-58. PubMed ID: 22987781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BACE1 and Other Alzheimer's-Related Biomarkers in Cerebrospinal Fluid and Plasma Distinguish Alzheimer's Disease Patients from Cognitively-Impaired Neurosyphilis Patients.
    Zhang M; Zhong X; Shi H; Vanmechelen E; De Vos A; Liu S; Chen B; Mai N; Peng Q; Chen X; Wu Z; Hou L; Zhou H; Ouyang C; Zhang W; Liang W; Dai C; Ning Y
    J Alzheimers Dis; 2020; 77(1):313-322. PubMed ID: 32804135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Cerebrospinal Fluid BACE1 Species.
    Lopez-Font I; Boix CP; Zetterberg H; Blennow K; Sáez-Valero J
    Mol Neurobiol; 2019 Dec; 56(12):8603-8616. PubMed ID: 31290061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BACE1: the beta-secretase enzyme in Alzheimer's disease.
    Vassar R
    J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The beta-secretase, BACE: a prime drug target for Alzheimer's disease.
    Vassar R
    J Mol Neurosci; 2001 Oct; 17(2):157-70. PubMed ID: 11816789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants.
    Timmers M; Barão S; Van Broeck B; Tesseur I; Slemmon J; De Waepenaert K; Bogert J; Shaw LM; Engelborghs S; Moechars D; Mercken M; Van Nueten L; Tritsmans L; de Strooper B; Streffer JR
    J Alzheimers Dis; 2017; 56(4):1437-1449. PubMed ID: 28157093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The β-Secretase Enzyme BACE1: A Biochemical Enigma for Alzheimer's Disease.
    Shah H; Patel A; Parikh V; Nagani A; Bhimani B; Shah U; Bambharoliya T
    CNS Neurol Disord Drug Targets; 2020; 19(3):184-194. PubMed ID: 32452328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revisiting the peripheral sink hypothesis: inhibiting BACE1 activity in the periphery does not alter β-amyloid levels in the CNS.
    Georgievska B; Gustavsson S; Lundkvist J; Neelissen J; Eketjäll S; Ramberg V; Bueters T; Agerman K; Juréus A; Svensson S; Berg S; Fälting J; Lendahl U
    J Neurochem; 2015 Feb; 132(4):477-86. PubMed ID: 25156639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-Secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification.
    Hampel H; Lista S; Vanmechelen E; Zetterberg H; Giorgi FS; Galgani A; Blennow K; Caraci F; Das B; Yan R; Vergallo A;
    Alzheimers Res Ther; 2020 Oct; 12(1):130. PubMed ID: 33066807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis.
    Deng Y; Wang Z; Wang R; Zhang X; Zhang S; Wu Y; Staufenbiel M; Cai F; Song W
    Eur J Neurosci; 2013 Jun; 37(12):1962-9. PubMed ID: 23773065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BACE1 as a potential biomarker for Alzheimer's disease.
    Decourt B; Sabbagh MN
    J Alzheimers Dis; 2011; 24 Suppl 2(Suppl 2):53-9. PubMed ID: 21403391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology.
    Mulder SD; van der Flier WM; Verheijen JH; Mulder C; Scheltens P; Blankenstein MA; Hack CE; Veerhuis R
    J Alzheimers Dis; 2010; 20(1):253-60. PubMed ID: 20164582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid profiles of amyloid β-related biomarkers in Alzheimer's disease.
    Rosén C; Andreasson U; Mattsson N; Marcusson J; Minthon L; Andreasen N; Blennow K; Zetterberg H
    Neuromolecular Med; 2012 Mar; 14(1):65-73. PubMed ID: 22350541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.